Morphotek is actively seeking partnerships with leading corporations, research organizations, and academic centers of excellence to identify and accelerate the discovery and development of new products. We have entered into multiple strategic collaborations with leading companies in diverse industries and with academic research organizations to gain access to and optimize products for potential future commercial use. In addition, the company is employing its technology for military and Homeland Security initiatives to develop proprietary molecules for the detection and treatment of pathogenic organisms used in biological warfare.

Partnership News

September 6, 2017

Morphotek Announces Collaboration Agreement with the Johns Hopkins University to Research and Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens
Read More

September 5, 2017

Morphotek, Inc. Announces an Agreement with Fujirebio Diagnostics, Inc to Commercialize the CA125 II Assay as A Companion Diagnostic for Farletuzumab
Read More

October 3, 2016

Morphotek and Eurofarma Laboratorios S.A. Sign Exclusive Licensing Agreement for Farletuzumab in Latin America
Read More

September 13, 2016

Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center to Study Immunosuppressive Effects of Tumor Shed Antigens to Improve Future Patient Therapies
Read More

March 31, 2016

Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies
Read More

February 3, 2016

Morphotek Announces Collaboration with Mayo Clinic
Read More

December 16, 2015

Morphotek, Inc. Announces an Agreement With Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Mesothelin in Malignant Tissues
Read More

December 3, 2015

Morphotek Announces Collaboration Agreement with University of Wisconsin-Madison to Study the Immunosuppressive Effects of CA125 Tumor Antigen on Immune-Based Therapies for Ovarian Cancer
Read More

November 17, 2015

Morphotek Announces Collaboration Agreement With University of Gothenburg to Develop Farletuzumab, an Investigational Anti-Folate Receptor Alpha Monoclonal Antibody, for Alpha-Particle Radioimmunotherapy in Ovarian Cancer
Read More

November 9, 2015

Morphotek, Inc. Announces a License Agreement With Blaze Bioscience Inc. For The Development of Novel Oncology Imaging Technology
Read More

Displaying results 1-10 (of 16)
 |<  < 1 - 2  >  >|